IO Biotech Inc
IOBT0.350USD
+0.030+9.27%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
24.39MMarket Cap
LossP/E TTM
More Details of IO Biotech Inc Company
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
IO Biotech Inc Info
Ticker SymbolIOBT
Company nameIO Biotech Inc
IPO dateNov 05, 2021
CEOZocca (Mai-Britt)
Number of employees80
Security typeOrdinary Share
Fiscal year-endNov 05
AddressOle Maaloes Veh 3
CityCOPENHAGEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryDenmark
Postal code2200
Phone4570702980
Websitehttps://www.iobiotech.com/
Ticker SymbolIOBT
IPO dateNov 05, 2021
CEOZocca (Mai-Britt)
Company Executives of IO Biotech Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+12000.00%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
+15000.00%
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Mr. David V. Smith
Mr. David V. Smith
Independent Director
Independent Director
--
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
--
--
Ms. Amy B. Sullivan
Ms. Amy B. Sullivan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Qasim Ahmad, M.D.
Dr. Qasim Ahmad, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+12000.00%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
+15000.00%
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
HBM Partners AG
5.48%
Chernett (Jorey)
4.83%
Ikarian Capital LLC
2.12%
Other
58.69%
Shareholders
Shareholders
Proportion
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
HBM Partners AG
5.48%
Chernett (Jorey)
4.83%
Ikarian Capital LLC
2.12%
Other
58.69%
Shareholder Types
Shareholders
Proportion
Venture Capital
29.12%
Investment Advisor
6.63%
Hedge Fund
5.28%
Individual Investor
5.14%
Investment Advisor/Hedge Fund
2.37%
Research Firm
1.26%
Other
50.20%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
52
34.65M
48.27%
-16.00M
2025Q3
49
42.06M
63.84%
-13.38M
2025Q2
52
43.99M
66.77%
-12.21M
2025Q1
56
44.00M
66.79%
+640.94K
2024Q4
57
44.61M
67.71%
+1.88M
2024Q3
50
48.46M
73.56%
+5.16M
2024Q2
48
51.73M
78.53%
+7.90M
2024Q1
53
52.99M
80.43%
+6.73M
2023Q4
55
54.27M
82.38%
+8.45M
2023Q3
56
56.33M
89.04%
+20.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lundbeckfond Ventures
13.95M
19.39%
--
--
Apr 11, 2025
Kurma Partners SA
6.82M
9.48%
--
--
Apr 11, 2025
HBM Partners AG
3.94M
5.48%
--
--
Apr 11, 2025
Chernett (Jorey)
3.48M
4.83%
+3.48M
--
Oct 30, 2025
Ikarian Capital LLC
1.53M
2.12%
+1.53M
--
Sep 30, 2025
Millennium Management LLC
1.39M
1.94%
+1.39M
--
Sep 30, 2025
Marshall Wace LLP
1.05M
1.46%
-1.05M
-50.00%
Sep 30, 2025
BofA Global Research (US)
799.95K
1.11%
-815.12K
-50.47%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
668.40K
0.93%
+14.72K
+2.25%
Sep 30, 2025
Boothbay Fund Management, LLC
591.18K
0.82%
+591.18K
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
